CLAIMS

1. Use of a compound, 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4- tetrahydrothieno [3,4d]pyrimidine-5-carboxylic acid, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for reducing endometriosis-associated pain in a female human patient having endometriosis, wherein the compound is to be administered to the patient in an amount of about 200 mg per day, wherein the patient is to be further administered add-back therapy comprising β17-estradiol and norethindrone acetate, wherein the β17-estradiol is to be administered to the patient in an amount of about 1.0 mg per day, and wherein the norethindrone acetate is to be administered to the patient in an amount of about 0.5 mg per day.

2. Use of a compound, 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4-methoxyphenyl]-2,4-dioxo-1,2,3,4- tetrahydrothieno [3,4d]pyrimidine-5-carboxylic acid, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating endometriosis in a female human patient, wherein the compound is to be administered to the patient in an amount of about 200 mg per day, wherein the patient is to be further administered add-back therapy comprising β17-estradiol and norethindrone acetate, wherein the β17-estradiol is to be administered to the patient in an amount of about 1.0 mg per day, and wherein the norethindrone acetate is to be administered to the patient in an amount of about 0.5 mg per day.

3. The use of claim 1 or 2, wherein the compound is to be administered to the patient in the form of a pharmaceutically acceptable salt thereof.

4. The use of claim 1 or 2, wherein the compound is to be administered to the patient in the form of a choline salt thereof.

5. The use of claim 1 or 2, wherein the compound is to be administered to the patient orally.

6. The use of claim 1 or 2, wherein the compound is to be administered to the patient once daily.

7. The use of claim 1 or 2, wherein the add-back therapy is to be administered to the patient once daily.

8. The use of claim 1 or 2, wherein the β17-estradiol is to be administered to the patient orally.

9. The use of claim 1 or 2, wherein the norethindrone acetate is to be administered to the patient orally.